| Prev Close | 76.67 |
| Open | 75.00 |
| Day Low/High | 69.77 / 75.35 |
| 52 Wk Low/High | 49.96 / 136.02 |
| Volume | 1.38M |
| Avg Volume | 637.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 85.72M |
| Market Cap | 6.69B |
| EPS | -3.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Alnylam Pharmaceuticals, Inc. Reports Inducement Grant To New Chief Operating Officer
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has granted stock options to Yvonne Greenstreet, the Company's newly appointed Chief Operating Officer.
Alnylam Expands And Strengthens Management Team As It Plans For Commercialization
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today two key appointments to its senior leadership team, expanding the breadth of talent and experience as the company...
Alnylam Reports Positive Interim Results From Ongoing Phase 1 Study Of ALN-AS1, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today interim data from its ongoing Phase 1 study with ALN-AS1, an investigational RNAi therapeutic targeting...
Alnylam To Webcast Presentations At Upcoming September Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Morgan Stanley Global...
Alnylam Completes Enrollment In ENDEAVOUR Phase 3 Study With Revusiran, An Investigational RNAi Therapeutic For Patients With Hereditary ATTR Amyloidosis With Cardiomyopathy (hATTR-CM)
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has completed enrollment in its ENDEAVOUR Phase 3 study with revusiran, an investigational RNAi therapeutic...
Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results And Highlights Recent Period Progress
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2016, and highlighted recent progress in advancing its...
Alnylam To Webcast Presentation At Canaccord Genuity Growth Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 36 th Annual Growth Conference on...
Perilous Reversal Stock: Alnylam Pharmaceuticals (ALNY)
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate
Alnylam To Webcast Conference Call Discussing Second Quarter 2016 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter on Thursday, August 4, 2016, after the U.
Alnylam Announces New Positive Interim Phase 1 Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new positive results from its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic targeting...
Today's Weak On High Volume Stock: Alnylam Pharmaceuticals (ALNY)
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate
Alnylam To Report New Clinical Results With Fitusiran At The World Federation Of Hemophilia (WFH) 2016 World Congress
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam and collaborators will present interim results from the ongoing Phase 1 clinical trial with fitusiran,...
5 Toxic Stocks to Sell as Anxiety Creeps Higher
It's time to unload these toxic stocks from your portfolio.
Alnylam To Host Third Annual "RNAi Roundtable" Webcast Series
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 3 rd Annual series of webcast "RNAi Roundtables" this summer and early fall.
Alnylam Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNAi...
Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Alnylam Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both...
Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate
Alnylam To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present preliminary results from its ongoing Phase 2 open-label...
Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
Cramer says you may be able to pick up a lot of high-quality stocks cheap this week.
'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
Cramer is interested in Monster Beverage and is avoiding Oasis Petroleum.
Alnylam Reports Initial ALN-CC5 Results In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) From Ongoing Phase 1/2 Study
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and collaborators today presented initial results from Part C of its ongoing Phase 1/2 clinical trial with ALN-CC5 - a...
Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1 clinical trial with ALN-TTRsc02, a subcutaneously administered investigational RNAi...
Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate
Stock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate
Alnylam To Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing...
Alnylam To Webcast Presentations At Upcoming June Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Goldman Sachs 37 th...
Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate
